Aims: Recent studies report that approximately 50% of patients with type 1 diabetes (T1D) are overweight or obese. This work studies the effects of intensive multidisciplinary weight management (IMWM) in patients with T1D and obesity. Results: Participants in the IMWM cohort had a body weight change of −6.6 AE 1.8 kg or −6.4% AE 1.6% of their initial body weight, while participants in the SC cohort had no change (P < 0.01 for group*time interaction). Participants in the IMWM cohort had a change in HbA1c of −0.4% AE 0.1% from baseline (P < 0.01), while participants in the SC cohort had no change. There was no difference in glycaemic control between cohorts at 12 months. Total daily insulin dose changed by −5.9 AE 1.8 units/d from baseline in the IMWM cohort while there was no change in the SC cohort (P < 0.01 for group*time interaction).
| INTRODUCTION
Type 1 diabetes (T1D) is characterized by progressive autoimmune destruction of insulin-producing pancreatic β cells, mandating use of exogenous insulin. 1, 2 Insulin, through its myriad of physiological effects, acts as a double-edged sword. 3 On the one hand, intensive insulin therapy (IIT) decreases the incidence of microvascular complications, 4 but on the other hand, it promotes weight gain. 5 Studies have shown that excess weight gain in patients with T1D who were under treatment with IIT was associated with development of central adiposity, insulin resistance and dyslipidaemia, all of which are hallmarks of metabolic syndrome and type 2 diabetes (T2D) in addition to being risk factors for cardiovascular disease (CVD). 6, 7 This phenomenon, which has been referred to as "double diabetes," has been increasingly recognized in patients with T1D. 8, 9 Although patients with T1D are typically thought of as being lean, or sometimes underweight, 10 recent studies demonstrated that roughly half of all patients with T1D were overweight or obese by *Adham Mottalib and Shaheen Tomah should be considered joint first authors.
2010. 11, 12 Several approaches for weight management were tested in patients with T1D and obesity, including intensive multidisciplinary weight management (IMWM) interventions. 13 We previously reported that patients with T2D who were enrolled in an IMWM programme, implemented within real-world clinical practice, demonstrated improvements in HbA1c and CVD risk factors after weight reduction. 14 However, it is not known whether IMWM would have similar effects in patients with T1D.
This retrospective study was designed to evaluate the effect of a 12-week multidisciplinary weight management intervention on body weight, glycaemic control, CVD risk factors and insulin requirements in patients with T1D and obesity in comparison to standard diabetes care in real-world clinical practice.
| MATERIALS AND METHODS

| Intensive multidisciplinary weight management intervention
The 
| Medication adjustment
Medications that promote weight gain were replaced, whenever possible, by medications that are weight neutral or that promote weight loss. 16 To insure patient safety, insulin doses were adjusted weekly by endocrinologists and nurse practitioners after careful review of blood glucose and dietary records. In patients treated with multiple daily insulin injections (MDI), long-acting insulin was switched to either detemir, degludec or glargine U300 insulin as these induce less weight gain in comparison to NPH or glargine U100 insulin. [17] [18] [19] To reduce compensatory overeating after insulin administration, participants were asked to inject short-acting insulin immediately after meals or within 20 minutes from the start of the meal. This allows insulin adjustment based on what patients actually ate rather than on what they assume they will eat. Pramlintide was prescribed to 64% of patients to reduce insulin doses and to suppress appetite. 20 Metformin was prescribed to 51% of patients as it has been shown to promote improvements in body weight and lipid profile in patients with T1D. 
| Behavioural intervention
Behavioural modification sessions were led by clinical psychologists or behavioural therapists who utilize validated cognitive-behavioural therapeutic methods for weight management. 24 , 25 The intervention included behavioural goal setting, self-monitoring of food intake and exercise, stimulus control techniques, cognitive restructuring, assertive communication skills, stress management and relapse prevention. 24, 25 At the conclusion of the Why WAIT programme, participants were encouraged to attend monthly support sessions to assist with long-term weight maintenance.
| Study participants
After approval of the institutional review board, we retrospectively evaluated all adult patients with T1D and obesity who were enrolled in the programme between September 2005 and August 2015. Seventy patients with T1D were enrolled in the programme during the study period. We excluded two patients from the analysis, one who became pregnant 4 months after starting the programme and the other who died from a suspected myocardial infarction 6 months after starting the programme and for whom there were data for only The only difference between cohorts at baseline was the method of insulin delivery, with the percentage of patients using insulin pump therapy being significantly higher in the IMWM cohort compared to the SC cohort (71% vs 41%; P < 0.001). There were data at baseline and at 12 months for all participants.
| Statistical analyses
No power calculation was necessary as all patients with T1D who enrolled in the IMWM programme were included in the analysis.
Demographic and baseline characteristics were evaluated using descriptive statistics. Continuous variables are reported as mean AE standard deviation (SD), as standard error of the mean (SEM) or as mean (95% confidence interval). Categorical variables are presented as percentages. For comparisons between the two study cohorts, an independent samples Student's t-test was used for continuous variables. Chi-square or Fisher's exact tests were used to compare categorical variables. A P value of <0.05 was considered statistically significant. To determine the possible influence of baseline differences on study outcomes, statistical analyses were run with and without adjustment for baseline age, BMI, T1D duration and method of insulin delivery. We found that adjusting for these variables had no effect on the direction or the significance of study conclusions. Statistical analysis was conducted using SAS version 9.4 for Windows (SAS Institute, Cary, North Carolina, 2012).
| RESULTS
After 12 months, participants in the IMWM cohort lost, on average, 6.6 AE 1.7 kg (95% CI, −10.3 to −3.0 kg; P < 0.001) which corresponded to a weight loss of 6.4% AE 1.6% (Figure 1 ). This was translated to a change in BMI of −2.0 AE 0.6 kg/m 2 (95% CI, −3.3 to −0.8 kg/m 2 ; P < 0.001) ( Table 2 ). Participants in the SC group had no change in body weight. The change in body weight at 1 year was significantly different between cohorts (P < 0.01). Changes in body weight and BMI remained significant in the IMWM cohort after adjusting for age, sex, T1D duration and method of insulin delivery.
Glycaemic control improved in the IMWM cohort compared to that at baseline (change in HbA1c of −0.4% AE 0.1%; 95% CI, −0.6 to −0.1; P < 0.01), with no change in the SC cohort. However, the difference in glycaemic control between cohorts at 12 months was not significant.
Total daily insulin dose decreased significantly from baseline in the IMWM cohort compared to the SC cohort (−5.9 AE 1.9 vs 2.0 AE 1.9 units/d; P < 0.01). Difference in daily insulin dose remained significant after adjusting for age, sex, BMI, T1D duration and method of insulin delivery. However, weight-adjusted insulin requirements did not change in either cohort at 12 months.
A single event of DKA was reported in the SC cohort only. There were no significant changes in blood pressure, renal function, lipid profile, utilization of antihypertensive and antihyperlipidaemic medications in either cohort at 12 months. However, the difference in utilization of antihypertensive medications between cohorts at 12 months was significant (P < 0.05).
| DISCUSSION
To our knowledge, this is the first study to evaluate the effect of nonsurgical weight management in patients with T1D and obesity. This study demonstrates that patients with T1D and obesity who participate in a 12-week IMWM programme within real-world clinical practice were able to achieve and maintain >6% weight loss at 1 year. This is of importance given that patients with T1D enrolled in the Diabetes
Control and Complication Trial/ Epidemiology of Diabetes Interventions and Complications (DCCT/EDIC) study, who received IIT and
were in the fourth quartile of weight gain, had a cumulative CVD event rate (but not a major adverse event rate) similar to that of the conventionally treated group, starting from year 14 of EDIC follow up. 26 We previously showed that patients with T2D who participated in the same IMWM programme achieved an average weight loss of 8.1% AE 7.5% at 1 year, 14 which was similar to the −8.6% change in weight at 1 year in the Look AHEAD (Action for Health in Diabetes) study. 27 Our results show that the magnitude of weight loss was lower in patients with T1D than in patients with T2D who were enrolled in the same IMWM programme. The difference may be related to the use of intensive insulin therapy, which was previously shown to promote weight gain in patients with T1D. 3 Although the degree of change in HbA1c did not differ between cohorts at 12 months, there was a modest, yet significant, improvement in glycaemic control compared to baseline in the IMWM cohort (HbA1c, −0.4% AE 0.1%; P < 0.01; 95% CI, −0.6% to −0.1%). The observed improvements in HbA1c rival those reported after bariatric surgery in patients with T1D and obesity. 28 Reduction in body weight was associated with a significant reduction in total daily insulin dose compared to the SC cohort. A similar reduction in total daily insulin intake was also observed in patients with T1D who underwent bariatric surgery. 28 Concerning weight loss, weight-adjusted insulin requirements did not change in the IMWM cohort. However, weightadjusted insulin requirements were reduced in patients with T1D after bariatric surgery. 28 This difference may be attributed to the greater magnitude of weight loss after bariatric surgery, 28 or may possibly be related to the unique physiological changes that follow these surgeries. 29 Furthermore, the observed changes in glycaemic control and daily insulin dose in this study are similar to those observed in a metaanalysis of six randomized controlled trials that evaluated the glycaemic effect of aerobic and resistance exercise in patients with T1D. per 100 person-years, respectively. 31 We did not observe a change in blood pressure or lipid profile in either cohort. It is worth noting that these parameters were within clinical goals at baseline. 32 Similarly, there was no change in kidney function in either cohort over 12 months. This may be explained by the slowly progressive nature of diabetic nephropathy in normotensive patients. 33 This study has several limitations, including its retrospective design and the fact that it was conducted at a single tertiary care centre. This IMWM programme requires a considerable time commitment and financial resources from its participants, which may limit the generalizability of these results. Additionally, data on the frequency and severity of hypoglycaemia during IMWM were not recorded in either cohort. This is especially important as fear of hypoglycaemia is a known barrier to exercise among patients with T1D, leading to a compensatory increase in food intake. 34, 35 At baseline, a higher percentage of IMWM cohort patients used insulin pump therapy. This may indicate a possible difference in socioeconomic status between cohorts. However, both cohorts had a similar racial/ethnic distribution. Furthermore, use of insulin pump therapy was adjusted for in the statistical analyses. Also, data on quality of life and measures of mental health were lacking because of the retrospective design of the study. Despite these limitations, the present study examined the effect of IMWM in patients with T1D, using the largest cohort of participants to date. The use of a matched cohort design minimized the confounders frequently seen in retrospective studies. Furthermore, the real-world nature of this study contributes to minimizing the discrepancies in effectiveness that are frequently noted between clinical trials and real-world clinical practice. 36 In conclusion, patients with T1D and obesity who undergo an IMWM within real-world clinical practice were able to achieve significant reductions in body weight, total daily insulin dose and number of antihypertensive medications after 1 year in comparison to those receiving standard care. Weight reduction was associated with significant improvement in glycaemic control compared to baseline. Longterm randomized prospective studies are warranted to confirm these findings and to examine the impact of intensive lifestyle interventions on morbidity and mortality in patients with T1D and obesity. have no disclosures relevant to this work.
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